Logo

Pharmoptima, Shamrock Form Joint Services Alliance

Oct 20, 2004

NEW YORK, Oct. 20 (GenomeWeb News) - PharmOptima and Shamrock Structures jointly announced today that they will offer each other's capabilities and services for drug discovery and research applications.

 

Woodbridge, Ill.-based Shamrock provides customers with proteomics services and access to X-ray synchrotron data collection. PharmOptima optimizes assays for high-throughput screening and is conducting research on its own portfolio of therapeutic products.

 

Terms of the agreement were not disclosed.

Breaking News
The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.